Multicenter Trial of Prednisone in Alzheimer's Disease
Information source: National Institute on Aging (NIA)
Information obtained from ClinicalTrials.gov on August 06, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Alzheimer Disease
Intervention: Prednisone (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: National Institute on Aging (NIA) Official(s) and/or principal investigator(s):
Leon Thal, MD., Principal Investigator, Affiliation: University of California, San Diego
Summary
This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.
Clinical Details
Official title:
Multicenter Trial of Prednisone in Alzheimer's Disease
Study design: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study
Eligibility
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with Alzheimer's disease who are in stable medical condition
Exclusion Criteria:
- Patients with diabetes or severe osteoporosis
Locations and Contacts
University of Alabama, Birmingham, Birmingham, Alabama 35294-0017, United States
University of Southern California, Los Angeles, California 90033, United States
University of California, San Diego, San Diego, California 92093-0949, United States
Mayo Clinic Jacksonville, Jacksonville, Florida 32225, United States
University of Miami, Miami, Florida 33140, United States
University of South Florida, Tampa, Florida 33162, United States
Indiana University Alzheimer's Center, Indianapolis, Indiana 46202, United States
University of Kansas Medical Center, Kansas City, Kansas 66160, United States
Johns Hopkins University, Baltimore, Maryland 21224, United States
University of Minnesota, Minneapolis, Minnesota 55455, United States
Washington University, St. Louis, Missouri 63110, United States
Mount Sinai Medical Center, New York, New York 10029, United States
Columbia Presbyterian Medical Center, New York, New York 11032, United States
New York University Medical Center, New York, New York 10016, United States
University of Rochester, Rochester, New York 14620, United States
Burke Medical Research Institute, White Plains, New York 10605, United States
University of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States
Vanderbilt University Medical Center, Nashville, Tennessee 37212-8646, United States
University of Texas, Dallas, Texas 75235-9070, United States
Additional Information
The Alzheimer's Disease Education and Referral (ADEAR) Center is a service of the National Institute on Aging (NIA).
Related publications: Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000 Feb 8;54(3):588-93.
Last updated: June 23, 2005
|
